High-DAR Antibody Conjugates via Single N-Glycan Click Chemistry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugate (ADC) technologies struggle to achieve homogeneous high payload loading (DAR) without genetic modification, leading to heterogeneous mixtures and poor pharmacokinetic properties.
Innovation Solution
A modular, non-genetic method involving enzymatic remodeling of the antibody's glycan to introduce click probes, followed by strain-promoted azide-alkyne cycloaddition and inverse electron-demand Diels-Alder cycloaddition to achieve site-specific conjugation of high DAR ADCs, up to 64, with a narrow distribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If stochastic conjugation methods are used to attach payloads to antibodies, then high payload loading (DAR) can be achieved, but the ADC becomes heterogeneous with poor pharmacokinetic properties
Solution Approach 1:
The patent applies local quality by introducing specific amino acid residues (non-natural amino acids containing azide or alkyne groups) at defined positions within the antibody structure. This enables site-specific conjugation where payloads are attached at predetermined locations rather than randomly throughout the antibody, achieving both high DAR and homogeneity simultaneously
Solution Approach 2:
The patent changes the chemical parameters of the antibody by incorporating non-natural amino acids with reactive functional groups (azide or alkyne). This parameter change enables selective chemical conjugation reactions with complementary payloads, transforming the conjugation process from stochastic to controlled and homogeneous
2Manufacturing precision
If genetic modification is used to achieve site-specific conjugation, then homogeneous high DAR ADCs can be produced, but the complexity of the manufacturing process increases
Solution Approach 1:
The patent applies preliminary action by pre-installing non-natural amino acid residues with reactive functional groups into the antibody structure during antibody production. This preliminary modification creates ready-to-conjugate sites that simplify the subsequent payload attachment process, avoiding the need for complex genetic engineering of the entire antibody gene
Solution Approach 2:
The patent uses non-natural amino acids as intermediary molecules that bridge the antibody and payload. These amino acids contain reactive functional groups (azide or alkyne) that serve as chemical mediators, enabling selective conjugation without requiring genetic modification of the antibody's core structure or function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces homogeneous ADCs with high payload loading, demonstrating improved pharmacokinetic profiles and in vitro/in vivo efficacy, overcoming the limitations of stochastic distribution and genetic engineering.
Implementation Method 1
enzymatic remodeling of the antibody's glycan to introduce click probes
Implementation Method 2
strain-promoted azide-alkyne cycloaddition
Implementation Method 3
inverse electron-demand Diels-Alder cycloaddition
Data Source
AI summary
The invention concerns homogenous antibody-conjugates with high payload loading (high DAR) obtained by site-specific conjugation to a single antibody N-glycan. The conjugates according to the invention are homogeneous, i.e. have a DAR at or close to the theoretical DAR with a narrow distribution, and do not require any genetic modification of the antibody. The invention further concerns a modular, non-genetic preparation method for such conjugates, involving three simple steps and starting from any antibody. These steps are (a) enzymatic remodeling of the glycan to give an antibody functionalized with two or four click probes per antibody, (b) strain-promoted cycloaddition with a multivalent, bifunctional reagent comprising one cyclic alkyne and at least two click probes that are not reactive towards the cyclic alkyne, and (c) inverse electron-demand Diels-Alder cycloaddition of the click probes with branched linker-drug constructs comprising one cyclic alkyne or strained alkene, connected to one or more payloads preferably connected through a cleavable linker. The resulting conjugates, with DAR6 or higher, are rapidly generated with high homogeneity and with surprising stability. In addition, HIC profiles of the resulting ADCs indicate small relative retention time and therefore show high potential in the targeting of tumour cells and/or the treatment of cancer.